Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD

被引：0
|
作者：
Calverley, PMA [1 ]
机构：
[1] Univ Hosp Aintree, Liverpool, Merseyside, England
来源：
THORAX | 2002年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
S145
引用
收藏
页数：1
相关论文
共 50 条
  • [31] The cost of moderate and severe COPD exacerbations to the Canadian healthcare system
    Mittmann, N.
    Kuramoto, L.
    Seung, S. J.
    Haddon, J. M.
    Bradley-Kennedy, C.
    FitzGerald, J. M.
    RESPIRATORY MEDICINE, 2008, 102 (03) : 413 - 421
  • [32] Ensifentrine Added on to LAMA Therapy Improved Lung Function and Reduced Exacerbations in Symptomatic Subjects With Moderate-to-Severe COPD
    Dransfield, M. T.
    Kalhan, R.
    Anzueto, A.
    Marchetti, N.
    Rheault, T.
    Reyner, D.
    Bengtsson, T.
    Rickard, K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [33] Onset and duration of action of formoterol and tiotropium in patients with moderate to severe COPD
    Richter, Kai
    Stenglein, Stephan
    Mueck, Marion
    Sieder, Christian
    Schmidtmann, Soeren
    Harnest, Ulf
    Weidinger, Gottfried
    Magnussen, Helgo
    RESPIRATION, 2006, 73 (04) : 414 - 419
  • [34] FORWARD: A study of extrafine beclomethasone/formoterol compared with formoterol alone in patients with severe COPD and a history of exacerbations
    Agusti, Alvar
    Corradi, Massimo
    Cohuet, Geraldine
    Vezzoli, Stefano
    Singh, Dave
    Vestbo, Jorgen
    Paggiaro, Pierluigi
    Jones, Paul
    Petruzzelli, Stefano
    Wedzicha, Jawidga
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [35] Rational timing of combination therapy with tiotropium and formoterol in moderate and severe COPD
    Terzano, Claudio
    Petroianni, Angelo
    Conti, Vittoria
    Ceccarelli, Daniela
    Graziani, Elda
    Sanduzzi, Alessandro
    D'Avelli, Serena
    RESPIRATORY MEDICINE, 2008, 102 (12) : 1701 - 1707
  • [36] Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate-to-severe type 2 asthma
    Papi, Alberto
    Corren, Jonathan
    Castro, Mario
    Domingo, Christian
    Rogers, Linda
    Chapman, Kenneth R.
    Jackson, Daniel J.
    Daizadeh, Nadia
    Pandit-Abid, Nami
    Gall, Rebecca
    Jacob-Nara, Juby A.
    Rowe, Paul J.
    Deniz, Yamo
    Ortiz, Benjamin
    ALLERGY, 2023, 78 (01) : 233 - 243
  • [37] Anti-inflammatory Effects of Combined Budesonide/Formoterol in COPD Exacerbations
    Bathoorn, Erik
    Liesker, Jeroen J. W.
    Postma, Dirkje S.
    Boorsma, Martin
    Bondesson, Eva
    Koeter, Gerard H.
    Kauffman, Henk F.
    van Oosterhout, Antoon J. M.
    Kerstjens, Huib A. M.
    COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2008, 5 (05) : 282 - 290
  • [38] Effect Of Budesonide/formoterol (bud/fm) Versus Fm Alone On The Rate Of Exacerbations (either Including Or Excluding The Use Of Antibiotics As Part Of Exacerbation Definition), Lung Function, And Rescue Medication Use In Patients With Moderate To Very Severe Chronic Obstructive Pulmonary Disease (COPD)
    Teshk, P.
    Rennard, S.
    Uryniak, T.
    Martina, U. J.
    Trudo, F.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [39] Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma
    Scicchitano, R
    Aalbers, R
    Ukena, D
    Manjra, A
    Fouquert, L
    Centanni, S
    Boulet, LP
    Naya, IP
    Hultquist, C
    CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (09) : 1403 - 1418
  • [40] Aclidinium Bromide Treatment in Patients Receiving Beta-Blockers: Effects on MACE, Moderate/Severe COPD Exacerbations, and Lung Function in Patients with Moderate-to-Very Severe COPD and Cardiovascular Risk Factors (ASCENT-COPD)
    Chapman, K. R.
    Wise, R. A.
    Scirica, B. M.
    Bhatt, D. L.
    Daoud, S. Z.
    Lythgoe, D.
    Garcia Gil, E.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
12345